JCM
NBIX icon

Jafra Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Jafra Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-11,184
Closed -$927K – 101
2018
Q1 		$927K Buy
11,184
+5,986
+115% +$505K 0.29% 72
2017
Q4 		$403K Sell
5,198
-14,802
-74% -$1.01M 0.11% 81
2017
Q3 		$1.23M Buy
+20,000
New +$1.06M 0.46% 56
2017
Q2 		– Sell
-12,500
Closed -$541K – 81
2017
Q1 		$541K Buy
+12,500
New +$536K 0.22% 54

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Jafra Capital Management's NBIX Position: Q2 2018 in Review

Jafra Capital Management sold out of Neurocrine Biosciences (NBIX) in Q2 2018, closing a stake of 11,184 shares — an estimated $927K sold.

Jafra Capital Management first reported a position in NBIX in Q1 2017 and held it in 4 quarters. The position peaked at $1.23M in Q3 2017. 274 funds tracked by Wall St. Rank hold NBIX as of Q2 2018.

  • Jafra Capital Management reported no remaining Neurocrine Biosciences position as of Q2 2018 after selling out during the quarter.
  • Jafra Capital Management sold 11,184 Neurocrine Biosciences shares in Q2 2018, an estimated $927K.
  • Jafra Capital Management first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 4 quarters.
  • Jafra Capital Management's Neurocrine Biosciences position peaked at $1.23M in Q3 2017.
  • 274 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2018.

Based on Jafra Capital Management's 13F filing for Q2 2018, filed 15 Aug 2018.